New therapeutic strategies for breast cancer;Cancer du sein: Nouveautes therapeutiques

Presse Medicale

Volumn 27, Issue 39, 1998, Pages 2049-2054

  Espie, M ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; LETROZOLE; MEGESTROL; PACLITAXEL; TAXANE DERIVATIVE; VOROZOLE; ANTHRACYCLINE; DRUG DERIVATIVE; TAXOID;

ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LEUKOPENIA; METASTASIS; NAUSEA; NEUROTOXICITY; SKIN MANIFESTATION; THROMBOCYTOPENIA; VOMITING; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; MORTALITY; MULTIDRUG RESISTANCE; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; NEOPLASM METASTASIS; PACLITAXEL; PROGNOSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 0032512347     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Le docetaxel (Taxotere R): revue pharmacologique preclinique: sort du médicament dans l'organisme et tolérance. Anticancer Drugs 1995 ; 6:339-68.
2. Jaffrezou JP, Laurent G. Docetaxel (Taxotere) ; current status and clinical prospects. Exp Opin Invest Drugs 1995 ; 4:1185-95.
3. Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P, Andre S.Preclinical evaluation of docetaxel (Taxoter). Sem Oncol 1995 ; 22:3-16.
4. Keams CM, Gianni L, Egorin MJ. Paclitaxel, Pharmacokinetics and pharmacodynamics. Semin Oncol 1995 ; 22:16-23.
5. Beijnen JH, Huizing MT, ten Bokkel Huinink WW et al. Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paditaxel (Taxol). Semin Oncol 1994 ; 21:53-62.
6. Holmes FA, Walters RS, Theriault RL et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991 ; 81:1797-805.
7. Holmes FA, Valero V, Theriault RL. Phase II trial of taxol in metastatic breast cancer refractory to multiple prior treatments. Proc Annu Meet Am Soc Clin Oncol 1993 ; 12:94.
8. Reichman BS, Seidman AD, Cown JP et al. Paclitaxel and recombinant human granulocyte colony stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993 ; 11:1943-51.
9. Seidman AD, Norton L, Reichman BS et al. Preliminary experience with paditaxel (Taxol) plus recombinant human granulocyte stimulating factor in the treatment of breast cancer. Semin Oncol 1993 ; 20(Suppl. 3):40-5.
10. Uziely B, Delaflor Weiss E, Lenz HJ et al. Paclitaxel (taxol) in refractory breast cancer response correlates with low levels of mdr 1 gene expression. Proc Annu Meet Am Soc Clin Oncol 1994 ; 13:75.
11. Gianni L, Capri G, Munzone E, Straneo M. Paclitaxel (taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines. Sem Oncol 1994 ; 21 (Suppl. 8): 29-33.
12. Fountzilas G.Taxol is effective in advanced breast cancer refractory to anthracyclines. A phase II study of the hellenic cooperative oncology group. Eur J Cancer 1994 ; 30A(Suppl.):A10.
13. Dieras V, Marty M, Tubiana N et al. Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer. Semin Oncol 1995 ; 22:33-9.
14. Nabholtz JM, Gelmon K, Botenbal M et al. Multicenter randomized comparative study of two doses of paclitaxel in patientes with metastatic breast cancer. J Clin Oncol 1996 ; 14:1858-67.
15. Wilson.Paclitaxel in doxorubicin refractory or mitoxantrone refractory breast cancer. A phase I/II trial of 96 hour infusion J Clin Oncol 1994 ; 8:1621-9.
16. Vermoken JB. High dose taxol with G-CSF in patients with advanced breast cancer refractory to anthracycline therapy. Eur J Cancer 1993 ; 29A(Suppl. 6):A 435.
17. Constenla M, Lorenzo I, Garcia-Arroyo FR, Ozores R. Phase II trial of paclitaxel 96-hour infusion with G-CSF in anthracycline-resistant metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol 1997 ; 16:165a.
18. Buzdar AU, Morris A, Hortobagyi GN et al. Prospective randomized trial of Taxol R alone versus fluorouracil, doxorubicin, cyclophosphamide as an induction therapy in patients with operable breast cancer. Proc Annu Meet Am Soc Clin Oncol 1997 ; 16:141a.
19. Gianni L, Capri G, Munzone E, Straneo M. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose finding and sequence finding study. J Clin Oncol 1995 ; 13:2688-99.
20. Sledge GW, Neuberg D, Ingle J, Martino S, Wood W. Phase III trial of doxorubicin vs. paditaxel vs. doxorubicin + paditaxel (as first-line therapy for metastatic breast cancer: an intergroup trial. Proc Annu Meet Am Soc Clin Oncol 1997 ; 16:1a.
21. Gamucci T, Piccart M, Brüning P et al. Single agent taxol versus doxorubicin as first-line chemotherapy in advanced breast cancer. Final results of an EORTC randomized study with crossover. Proc Annu Meet Am Soc Clin Oncol 1998 ; 17:111a.
22. Mickiewicz E, Di Noto M, Bas C et al. Taxol R (paclitaxel) 1-hour infusion plus doxorubicin as first lilne treatment for metastatic breast cancer (MBC) patients, ECCO. Hambourg, 1997, pp 677.
23. Latorre A, Lorusso V, Guida M et al. Paclitaxel and doxorubicin in the treatment of advanced breast cancer: a phase I/II study. Proc Annu Meet Am Soc Clin Oncol 1997 ; 16:179a.